[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Benef](https://github.com/mm80843/T3.5/tree/pages/docs/Benef/index.md) >> Individual ID:PBN__Benef_1117 

# __Removal of other respiratory pathogens__

## Articles mentionning this Benefit

* [The removal of airborne SARS-CoV-2 and other microbial bioaerosols by air filtration on COVID-19 surge units](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_232.md)

## Category to which it belongs

* [Effective control and elimination of infectious pathogens to prevent disease transmission and reduce the overall risk of infection.](https://github.com/mm80843/T3.5/blob/pages/PBNCategory/PBN__PBNCategory_1.md)

## Description of actual returns pertaining to this benefit

* [Private investors would benefit from investing in air filtration devices as it would improve patient safety, attract more patients, and reduce healthcare costs associated with infections.](https://github.com/mm80843/T3.5/blob/pages/BenefReturn/PBN__BenefReturn_1252.md)

## Name of the Benefit

Air filtration devices remove a broad range of bacterial, viral, and fungal pathogens from the air, reducing the risk of hospital-acquired respiratory infections.

## Risks which can benefit from this action

* [Air filtration and uv light sterilisation](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_1129.md)

## Stakeholders benefitting from this Benefit

* [Healthcare workers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_68.md)
* [Patients](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_31.md)

